Skip to main content

Advertisement

SpringerLink
Log in

Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy

  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

A phase II study was undertaken to evaluate the clinical efficacy and safety of docetaxel in patients with malignant melanoma. Between April 1992 and February 1996, 37 patients with metastatic malignant melanoma and no prior chemotherapy were treated with docetaxel 100 mg m-2 administered intravenously over 1 hour every 21 days. Patients were premedicated prior to each course with dexamethasone and diphenhydramine. Toxicity and follow-up were provided. Objective responses were seen in two out of 35 patients evaluable for response, one complete response and one partial response. These two responses were of a duration of greater than two years. The most common toxicity was grade 4 neutropenia, which occurred in 92% of patients; 49% required hospitalization for an episode of neutropenic fever. Additional patients had reversible grade 3–4 toxicities including nausea, vomiting, diarrhea, stomatitis, arthralgias, myalgias, peripheral neuropathy and fatigue. Eighteen patients had hypersensitivity reactions, two were grade 3–4. Fluid retention, grade 1–3 was observed in seven patients. Alopecia occurred in most patients. Docetaxel has definite but low-level activity against malignant melanoma. Further investigation of this drug should be considered in multidrug combination programs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Karjalainen, S. and Hakulinen, T. (1988) Survival and prognostic factors of patients with skin melanoma.Cancer 62, 2274.

    Article  PubMed  CAS  Google Scholar 

  2. Marsoni, S., Hoth, D. and Simon, R. (1987) Clinical drug development: An analysis of phase II trials, 1970–1985.Cancer Treat. Rep. 71, 71.

    PubMed  CAS  Google Scholar 

  3. Bissery, M.C., Bayssas, M., Lavelle, F.et al. (1990) Preclinical evaluation of intravenous Taxotere (RP 56976, WSC 628503) a Taxol analog.Proc. Am. Assoc. Cancer Res. (abstr.)31, 417.

    Google Scholar 

  4. Extra, J.M., Rousseau, F., Bruno, R.et al. (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.Cancer Res. 53, 1037- 42.

    PubMed  CAS  Google Scholar 

  5. Bisset, D., Setanoians, A., Cassidy, J.et al. (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion.Cancer Res. 53, 523–7.

    Google Scholar 

  6. Pazdur, R., Newmann, R.A., Newmann, B.M.et al. (1992) Phase I trial of Taxotere, five day schedule.J. Natl. Cancer Inst. 84, 1781–8. 7 Burris, H.A., Irvin, R., Kuhn,J. et al. (1993) Phase I trial of Taxotere administered as either a 24-hour or 6-hour infusion.J. Clin. Oncol. 11, 950-8.

    Article  PubMed  CAS  Google Scholar 

  7. Tomiak, E., Piccart, M.J., Kerger, J.et al. (1994) Phase I study of docetaxel administered as an intravenous 1-hour infusion on a weekly basis.J. Clin. Oncol. 12, 1458–67.

    PubMed  CAS  Google Scholar 

  8. Francis, P.A., Rigas, J.R., Kris, M.G.et al. (1994) Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer.J. Clin. Oncol. 12, 1232–7.

    PubMed  CAS  Google Scholar 

  9. Fossella, F.V., Lee, J.S., Murphy, W.K.et al. (1994) Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer.J. Clin. Oncol. 12, 1238–44.

    PubMed  CAS  Google Scholar 

  10. Fossella, F.V., Lee, J.S., Shinn, D.M.et al. (1995) Phase II study of docetaxel for advanced or metastatic platinum- refractory non-small cell lung cancer.J. Clin. Oncol. 13, 645–51.

    PubMed  CAS  Google Scholar 

  11. Cerny, T., Kaplan, S., Pavlidis, N.et al. (1994) Docetaxel (Taxotere) is active in non-small cell lung cancer: A phase II study of the EORTC early clinical trials group (ECTG).Br. J. Cancer 70, 384–7.

    PubMed  CAS  Google Scholar 

  12. Fossella, F.V., Lee, J.S., Berille, J.et al. (1995) Summary of the phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of non-small cell lung cancer.Semin. Oncol. (suppl 4)22, 22–29.

    PubMed  CAS  Google Scholar 

  13. Ten Bokkel Huinink, W., Prove, A.M., Piccart, M.et al. (1994) A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer.Ann. Oncol. 5, 527–32.

    PubMed  Google Scholar 

  14. Chevalier, B., Fumoleau, P., Kerbrat, P.et al. (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for the Research and Treatment of Cancer.J. Clin. Oncol. 13, 314–22.

    Google Scholar 

  15. Dieras, V., Fumoleau, P., Chevalier, B.et al. (1994) Second EORTC Clinical Screening Group (CSG) phase II trial of taxotere (docetaxel) as first line chemotherapy in advanced breast cancer.Proc. Am. Soc. Clin. Oncol. (abstr.)13, 78.

    Google Scholar 

  16. Trudeau, M.E., Eisenhauer, E., Lofters, W.et al. (1993) Phase II study of Taxotere as first-line chemotherapy for metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study.Proc. Am. Soc. Clin. Oncol. (abstr.)12, 64.

    Google Scholar 

  17. Seidman, A.D., Hudis, C., Crown, J.P.et al. (1993) Phase II evaluation of Taxotere (RP 56976, NSC 628503) as initial chemotherapy for metastatic breast cancer.Proc. Am. Soc. Clin. Oncol. (abstr.)12, 63.

    Google Scholar 

  18. Ravdin, P.M. and Valero, V. (1995) Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.Semin. Oncol. (suppl 4)22, 17–21.

    PubMed  CAS  Google Scholar 

  19. Francis, P., Schneider, J., Hann, L.et al. (1994) Phase II trial of docetaxel in patients with platinum refractory ovarian cancer.J. Clin. Oncol. 12, 2301–8.

    PubMed  CAS  Google Scholar 

  20. Piccart, M.J., Gore, M., ten Bokkel Huinnink, W.et al. (1995) Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer.J. Natl. Cancer Inst. 87, 676–81.

    Article  PubMed  CAS  Google Scholar 

  21. Catimel, G., Vermeij, J., Mattijsen, V.et al. (1994) Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck.Ann. Oncol. 5, 533–7.

    PubMed  CAS  Google Scholar 

  22. McCaffrey, J., Hilton, S., Bajorin, D.et al. (1995) Docetaxel in patients with advanced transitional cell cancer (TCC) who failed cisplatin-based chemotherapy: A phase II trial.Proc. Am. Soc. Clin. Oncol. (abstr.)14, 233.

    Google Scholar 

  23. Sulkes, A., Smyth, J., Sessa, C.et al. (1994) Docetaxel (Taxotere) in advanced gastric cancer: Result of phase II clinical trial.Br. J. Cancer 70, 380–3.

    PubMed  CAS  Google Scholar 

  24. Oken, M.M., Creech, R.H., Tormey, D.C.et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am. J. Clin. Oncol. 5, 649–55.

    Article  PubMed  CAS  Google Scholar 

  25. Bedikian, A.Y., Weiss, G.R., Legha, S.S.et al. (1995) Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.J. Clin. Oncol. 13, 2895–9.

    PubMed  CAS  Google Scholar 

  26. Aamdal, S., Wolff, I., Kaplan, S.et al. (1994) Docetaxel (Taxotere) in advanced malignant melanoma: A phase II study of the EORTC Early Clinical Trials Group.Eur. J. Cancer 30A, 1064–7.

    Google Scholar 

  27. Comis, R.L. (1976) DTIC In malignant melanoma: A perspective.Cancer Treat. Rep. 64, 1123.

    Google Scholar 

  28. Luce, J.K. (1972) Chemotherapy of malignant melanoma.Cancer 30, 1604.

    Article  PubMed  CAS  Google Scholar 

  29. Costonza, M.E., Nathanson, L., Schoenfeld, D.et al. (1977) Results with methyl-CCNU and DTIC in metastatic melanoma.Cancer 40, 1010.

    Article  Google Scholar 

  30. Hill, G.J. II, Krementz, E.T. and Hill, H.Z. (1984) Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma: Late results after complete response to chemotherapy.Cancer 53, 1299.

    Article  PubMed  Google Scholar 

  31. Kirkwood, J.M. and Ernstoff, M. (1986) Potential application of the interferons in oncology: Lessons drawn from studies of human melanoma.Semin. Oncol. 13, 48.

    PubMed  CAS  Google Scholar 

  32. Creagan, E.T., Ahman, D.L., Frytak, S.et al. (1986) Recombinant A interferon (IFN-alpha 2A) in the treatment of disseminated malignant melanoma: Analysis of complete and long-term responding patients.Cancer 58, 2576.

    Article  PubMed  CAS  Google Scholar 

  33. Rosenberg, S.A., Lotee, M.T., Muul, L.M.et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone.N. Engl. J. Med. 316, 889.

    PubMed  CAS  Google Scholar 

  34. Dutcher, J.P., Gaynor, E., Boldt, D.H.et al. (1991) A phase II study of high-dose continuous infusion interleukin-2 with lymphokine activated killer cells in patients with metastatic melanoma.J. Clin. Oncol. 9, 641.

    PubMed  CAS  Google Scholar 

  35. Dutcher, J.P., Creekmore, S., Weiss, G.R.et al. (1989) A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic melanoma.J. Clin. Oncol. 7, 477.

    PubMed  CAS  Google Scholar 

  36. Einzig, A.I., Hochster, H., Wiernik, P.H.et al. (1991) A phase II study of Taxol in patients with malignant melanoma.Invest. New Drugs 9, 59–64.

    Article  PubMed  CAS  Google Scholar 

  37. Legha, S.S., Ring, S., Papadeopoulos, N.et al. (1990) A phase II study in patients with metastatic melanoma.Cancer 65, 2478–81.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Albert Einslein Cancer Center and Department of Oncology, Montefiore Medical Center, 1825 Eastchester Road, 10461, Bronx, New York, USA

    Avi I. Einzig, Susan Coatsworth & Peter H. Wiernik

  2. Department of Oncology, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA

    Lynn M. Schuchter, Adri Recio & Roberto Rodriquez

Authors
  1. Avi I. Einzig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lynn M. Schuchter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adri Recio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Susan Coatsworth
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Roberto Rodriquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter H. Wiernik
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Einzig, A.I., Schuchter, L.M., Recio, A. et al. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Med Oncol 13, 111–117 (1996). https://doi.org/10.1007/BF02993861

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02993861

Keywords

Search

Navigation